Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25823363 | 0.84 | MCHR1 (0.42) | CACNA2D1LOXL2AAK1 | |
| SCHEMBL25827570 | 0.81 | LOXL2 (0.42) | CACNA2D1LOXL2AAK1 | |
| SCHEMBL23716938 | 0.79 | CNR2 (0.46) | IDO1MAPTHTTKMT2ASMN1; SMN2 | |
| SCHEMBL7510055 | 0.78 | LOXL2 (0.40) | MAPTKMT2AKDM4ELOXL2MEN1 | |
| SCHEMBL21834887 | 0.78 | CNR2 (0.47) | IDO1MAPTHTTKMT2ASMN1; SMN2 | |
| SCHEMBL21834885 | 0.78 | CNR2 (0.47) | IDO1MAPTHTTKMT2ASMN1; SMN2 | |
| SCHEMBL13630892 | 0.77 | NCF1 (0.43) | IDO1MAPTSMN1; SMN2LOXL2AAK1 | |
| SCHEMBL3271690 | 0.77 | IDO1 (0.45) | IDO1LOXL2 | |
| SCHEMBL12282776 | 0.77 | MAPT (0.47) | MAPTHTTKMT2ASMN1; SMN2LOXL2 | |
| SCHEMBL10666637 | 0.75 | KDM4E (0.45) | MAPTKMT2ASMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-11-04 | — | — | US | disclosed |
| US-20220041576-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-02-10 | — | — | US | disclosed |
| EP-3862348-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459921-B2 | Isoindoline compound, preparation method, pharmaceutical composition and use thereof | CUL4B, CUL4A, UBQLN1 | IDO1 217/4885CACNA2D1 4192/4885MAPT 2018/4885 |
| US-20220041576-A1 | ISOINDOLINE COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | CUL4B, CUL4A, UBQLN1 | IDO1 217/4885CACNA2D1 4192/4885MAPT 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.